Skip to content
Catalyst

caseinFinding

Casein has no detected effect on adverse event occurrence (oral or enteral supplement)

no difference foundModerate evidenceFinding

01 · The sentence it was drawn from

“There was no significant difference in the incidence of adverse events between the two groups (MKP group; 65.0%, placebo group; 59.3%, p > 0.1).”
Quoted verbatim from Effects of Casein-Derived Peptide Met-Lys-Pro on Systolic and Diastolic Blood Pressure: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
This finding among the 13 findings on its endpoint

casein

Adverse event occurrence (oral or enteral supplement)

no difference found

Who
Healthy Japanese adults aged 20 to 74 with high-normal or elevated blood pressure, safety analysis set, 12 weeks
Dose studied
one sachet once daily containing 100 ug Met-Lys-Pro, taken with a drink, 12 weeks

Moderate evidencePMID 39275290 · 2024

02 · The study

Study
RCT
Duration
3 months

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M7EWQ8VD92D66C50F9HSR1VN